Dong-Hua Mi1, Hong-Juan Fang2, Guang-Hui Zheng3, Xian-Hong Liang1, Ya-Rong Ding1, Xin Liu1, Li-Ping Liu1. 1. Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. 2. Department of Endocrinology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. 3. Department of Clinical laboratory, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Abstract
BACKGROUND: Vascular disease in diabetes, for example, stroke, presents a significant public health burden. Recently, the dipeptidyl peptidase 4 (DPP-4) inhibitor linagliptin has been found to counteract stroke among diabetic patients, showing great promise in drug repurposing and indication expansion. However, the molecular basis of this protection mechanism remains unknown. METHODS: The expression and localization of DPP-4 in rat brain microvascular endothelial cells (rBMVECs) were assessed with immunofluorescent staining and Western blotting. The effects of DPP-4 inhibitors on cell proliferation and migration of rBMVECs were determined using MTT and transwell assays, separately. The influence of DPP-4 inhibition on the expression of molecular markers (eg, VEGF, eNOS, HIF-1α. SIRT1) was examined at both mRNA and protein levels with qRT-PCR and Western blotting, individually. RESULTS: DPP-4 inhibitors (40 nmol/L linagliptin, 30 μmol/L berberine) offer protection from hypoxia/high glucose induced impairments in the proliferation and migration of rBMVECs. Treatment with DPP-4 inhibitors counteracted the attenuating effects of hypoxic/high-glucose conditions on the expression of VEGF, eNOS, HIF-1α, and SIRT1, which can be completely eliminated by the inhibition of SIRT1 with 1 mmol/L nicotinamide. CONCLUSIONS: The protection of rBMVECs from hypoxia/high-glucose induced impairment by DPP-4 inhibitors may be mediated by the SIRT1/HIF-1α/VEGF pathway.
BACKGROUND:Vascular disease in diabetes, for example, stroke, presents a significant public health burden. Recently, the dipeptidyl peptidase 4 (DPP-4) inhibitor linagliptin has been found to counteract stroke among diabeticpatients, showing great promise in drug repurposing and indication expansion. However, the molecular basis of this protection mechanism remains unknown. METHODS: The expression and localization of DPP-4 in rat brain microvascular endothelial cells (rBMVECs) were assessed with immunofluorescent staining and Western blotting. The effects of DPP-4 inhibitors on cell proliferation and migration of rBMVECs were determined using MTT and transwell assays, separately. The influence of DPP-4 inhibition on the expression of molecular markers (eg, VEGF, eNOS, HIF-1α. SIRT1) was examined at both mRNA and protein levels with qRT-PCR and Western blotting, individually. RESULTS:DPP-4 inhibitors (40 nmol/L linagliptin, 30 μmol/L berberine) offer protection from hypoxia/high glucose induced impairments in the proliferation and migration of rBMVECs. Treatment with DPP-4 inhibitors counteracted the attenuating effects of hypoxic/high-glucose conditions on the expression of VEGF, eNOS, HIF-1α, and SIRT1, which can be completely eliminated by the inhibition of SIRT1 with 1 mmol/L nicotinamide. CONCLUSIONS: The protection of rBMVECs from hypoxia/high-glucose induced impairment by DPP-4 inhibitors may be mediated by the SIRT1/HIF-1α/VEGF pathway.
Authors: T Forst; B Uhlig-Laske; A Ring; U Graefe-Mody; C Friedrich; K Herbach; H-J Woerle; K A Dugi Journal: Diabet Med Date: 2010-12 Impact factor: 4.359
Authors: Juan A Orellana; Diego E Hernández; Pascal Ezan; Victoria Velarde; Michael V L Bennett; Christian Giaume; Juan C Sáez Journal: Glia Date: 2010-02 Impact factor: 7.452
Authors: Michał Wiciński; Karol Górski; Maciej Walczak; Eryk Wódkiewicz; Maciej Słupski; Katarzyna Pawlak-Osińska; Bartosz Malinowski Journal: Int J Mol Sci Date: 2019-08-20 Impact factor: 5.923